Investigational drug · Phase 2
YR001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "YR001"
First trial start
2024
Jun 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YR001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "YR001" as an intervention, largest first.
Hangzhou Yirui Pharmaceutical Technology Co., LtdIndustry
NCT05718921 · 54 participants · Start Apr 8, 2023 · Primary completion Aug 14, 2023
Drug: YR001 Dose A on low body surface area; YR001 Dose A on middle body surface area and 10 more · For: Atopic Dermatitis; Psoriasis
Sites: Encinitas, California
Hangzhou Yirui Pharmaceutical Technology Co., LtdIndustry
NCT06309355 · 35 participants · Start Jun 19, 2024 · Primary completion Nov 20, 2025
Drug: YR001 ointment · For: Atopic Dermatitis
Sites: Boynton Beach, Florida; Hollywood, Florida; Weston, Florida · 4 sites in all
Hangzhou Yirui Pharmaceutical Technology Co., LtdIndustry
NCT07673458 · 18 participants (planned) · Start Jun 22, 2026 · Primary completion Sep 18, 2026
Drug: PA032; Vehicle Ointment · For: Health Adult Subjects
Sites: Langfang, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.